Introduction In the US, Alzheimer’s disease (AD) has been established to be the most prevalent type of dementia. Present estimates show that approximately five million Americans have AD. The majority of affected people are above 65 years of age with the commonality level increasing as age advances. This signifies that in the aging baby boomer generation, about 60% of people above 85 years old in the year 2050, which translates to around 15 million individuals, will be living with AD (Ooms and Ju 15). Medicines used in the treatment of negative behavioral practices of AD and in slowing the continued progression of the disease are usually linked to side effects that result in sleep disorders. Therefore, most people with AD usually have difficulties with sleeping or might encounter variations in their sleep plan. The multimorbidity, co-occurrence of AD and sleep disorder, has been approximated to affect more than 90% of the primary care population from 65 years and above earlier living with Alzheimer’s alone. There is a need for effective treatment of AD-sleep disorder multimorbidity to prevent polypharmacy and improve the health condition of patients. The Occurrence of Multimorbidity Most people living with AD experience problems in their sleep cycles. Scientists and researchers do not fully comprehend why multimorbidity arises. Similar to variations in behavior and memory, sleep variations somehow emanate from the effects of AD on the brain. Although most of the older adults who do not have Alzheimer’s also experience some sleep-associated problems, the disorder arises more frequently and tends towards being more severe in the ones living with AD (Brzecka et al. 8). There is proof that sleep disorders are more prevalent in later phases of AD, but research studies have established some occurrences in the early stages. Acetylcholinesterase inhibitors, for instance, donepezil, have been determined to slow cognitive decline in some people with Alzheimer’s but may lead to nighttime stimulation over and above being linked to incidences of dream disturbances. Uncharacteristic antipsychotic drugs such as risperidone and olanzapine raise daytime somnolence and fatigue. The utilization of such medicines should be personalized anchored in the status of patients, behavioral manifestations of severity, and sensitiveness to side effects. AD is linked to increased delays in circadian rhythms, contrary to the characteristic advancements in the cycle with age. Such delays have the probability of contributing to sundowning, that is, confusion and anxiety in the evening, in addition to problems sleeping in the nighttime. Attributable to wandering and the ensuing possibility of injury, the occurrence of insomnia at night affects mortality and morbidity directly, which forms a strong basis for institutionalization (Okuda et al. 1493). Excessive sleepiness during the day might lead to poor cognitive function, unintended naps that negatively influence safety when driving, and reduced capacity to take part in social tasks and therapies. One of the commonest sleep disorders for people living with AD is difficulty sleeping. In this condition, patients with AD wake up more frequently and remain awake for a long time at night. In such situations, brain waves establish reductions in both non-dreaming and dreaming sleep cycles. Older adults who have difficulty sleeping might wander, find it uncomfortable to lie still for a long time, call out, or shout thus interrupting the normal sleep of their carers. Another sleep disorder for AD patients is daytime napping, as well as other alterations in the sle